1.HKU ya ce ana iya hada maganin COVID-19 na hanci da kuma rigakafin mura zuwa daya
Shi rigakafin COVID-19 na hanci wanda Jami'ar Hong Kong, Jami'ar Xiamen da Beijing Wantai Biological Pharmaceutical Co., Ltd suka kirkira kwanan nan daga Hukumar Kula da Magunguna ta Jiha don amfani da gaggawa a cikin babban yankin.Jami'ar Hong Kong ta mayar da martani ga binciken wakilin ma'aikatar labarai ta kasar Sin cewa daya daga cikin halayen wannan rigakafin COVID-19 na hanci shi ne, ana iya hada shi da maganin mura.
2.Waterloo, nau'in biliyan 3, ya haifar da sabon "kambin tallace-tallace" na antiemetics!
Tashin zuciya da amai da chemotherapy ke haifarwa na ɗaya daga cikin mummunan halayen masu cutar kansa.Magungunan anti-emetic da anti-ciwon ciki, an rarraba su a matsayin tsarin narkewar abinci da kuma magunguna na rayuwa, amma ana amfani da su a cikin maganin amai da magungunan ciwon daji ke haifarwa a aikin asibiti, kuma suna taka muhimmiyar rawa a fannin maganin ciwon daji.Alkaluman da aka fitar daga Minei.com sun nuna cewa, girman kasuwan da magungunan kashe gobara da maganin tashin hankali a tashoshin cibiyoyin kiwon lafiya na jama'a a kasar Sin a farkon rabin shekarar 2022 ya zarce yuan biliyan 2.9.Qilu Pharmaceutical ya ci gaba da jagorantar kasuwa.Zhengda Tianqing Pharmaceutical Group ya garzaya zuwa TOP2.Sabbin magunguna na Class 1 na Hengrui sun shiga aikin asibiti na Phase III, kuma sabon zagaye na shuffling yana gab da farawa.
3.Double anti R & D waƙa yana da zafi!Xinda da wasu kamfanoni sun sami kasuwa fiye da biliyan 200
Kwanan nan, kasuwar maganin miyagun ƙwayoyi biyu ta kasance mai zafi: Kangfang Biotech da Summit Therapeutics sun cimma yarjejeniyar ba da lasisi a ketare har dalar Amurka biliyan 5 don samfurin maganin miyagun ƙwayoyi guda biyu AK112, da Wuhan Youzhiyou Biotech, wani bincike da haɓaka maganin magungunan gida biyu. sha'anin, ya ƙaddamar da IPO jeri aikace-aikace… Kore da m kasuwa, da dual anti miyagun ƙwayoyi kuma maraba da bincike da ci gaban albarku.A halin yanzu, akwai kusan nau'ikan rigakafi guda 80 a matakin asibiti a kasar Sin.Xinda Bio, Shiyao Holding, Roche, da dai sauransu suna da samfura huɗu ko fiye a ƙarƙashin bincike.Samfura goma sha uku na Hengrui Pharmaceutical, kamar SHR-1701, Zanidatamab na Baiji Shenzhou, suna cikin asibiti na kashi III.Kwayoyin rigakafi guda biyu bisa tushen CD47/PD-L1 sune mafi mashahuri, kuma samfuran biyar suna fuskantar gwaji na asibiti.CDE ta tsara jerin ƙa'idodin jagora don batutuwan da ke buƙatar kulawa cikin gaggawa a cikin binciken asibiti da haɓaka magungunan rigakafin ƙwayar cuta guda biyu, Don jagorantar kamfanoni don gudanar da ƙarin bincike na asibiti na kimiyya da haɓaka rigakafin rigakafi biyu.
4.Mafi munin cutar mura a cikin shekaru goma da suka gabata ta buge!Yawan asibitocin da ake kwantar da su a jihohin Amurka ya karu
A cewar rahoton a lokaci na 5 na Axios, gidan yanar gizon labarai na Amurka, mura mafi muni a cikin shekaru fiye da goma ya afka cikin tsarin kiwon lafiya da na kiwon lafiya da ke gab da rugujewa sakamakon annobar COVID-19 da na numfashi. cutar (RSV).
An ba da rahoton cewa mura ya yi kusan kowace jiha a matakin girma ko kuma mai girma na ayyukan mura.
A cewar Cibiyar Kula da Cututtuka da Cututtuka ta Amurka (CDC), adadin asibitocin da ke da alaƙa da mura a lokacin godiya ya kusan ninka sau biyu daga makon da ya gabata, mafi girma tun lokacin mura na 2010-2011.Daga cikinsu, manya masu shekaru 65 zuwa sama da yara masu shekaru 4 zuwa kasa sun fi fama da cutar, musamman idan suna da matsalolin lafiya.
Duk da haka, kusan kashi 40% na Amurkawa sun ce ba su yi shirin yin allurar rigakafin mura a wannan kakar ba, musamman saboda sun damu da rashin tasiri ko illar maganin.
Masana kiwon lafiyar jama'a sun ce a cikin shekaru biyu da suka gabata, abin rufe fuska da sauran matakan rigakafin cutar ta COVID-19 sun dakile cutar mura tare da toshe yaduwar sa a lokutan lokaci.Koyaya, yayin da mutane ke komawa rayuwarsu kafin barkewar cutar, su ma sun fi kamuwa da kamuwa da cuta.
A bara, wata ƙungiyar bincike ta yi hasashen cewa da zarar an cire matakan kariya na sirri, yanayin cutar da yara zai sake farfadowa sosai.Masu binciken sun bukaci aiwatar da wani "tsarin rigakafi mai biyo baya" mai karfi.
CDC ta kiyasta cewa, ya zuwa yanzu, aƙalla mutane miliyan 8.7 sun kamu da rashin lafiya, 78000 kuma an kwantar da su a asibiti kuma 4500 sun mutu a lokacin mura.
A cewar CNN, gwamnatin Biden ta yi alƙawarin samar da albarkatu da ma'aikata don taimakawa tsarin kiwon lafiyar gida don shawo kan matsalar mura, amma ba za ta yi la'akari da ayyana dokar ta-baci ta lafiyar jama'a ba.
Dangane da bayanan CDC, tsakanin 2009 da 2022, adadin asibitocin mura na manya Ba’amurke ya kusan 80% sama da na manya farare.Koyaya, yayin lokacin mura na 2021-2022, ƙasa da kashi 43% na Ba'amurke Ba'amurke, Hispanic da ƴan asalin Amurkawa balagaggu an yi musu rigakafin.
A cikin wata wasika da ya aike wa jihohin, Sakataren Ma’aikatar Lafiya da Ayyukan Jama’a na Amurka, Xavier Bessela, ya rubuta cewa gwamnatin tarayya za ta iya shiga tsakani don taimakawa tsarin kiwon lafiyar da ke fuskantar matsin lamba, kamar barin asibitocin da ke da karancin ma’aikata su ji dadin kebewa don kara karuwa. da ikon kula da marasa lafiya, ko sanya su mafi kusantar canja wurin marasa lafiya da mura, COVID-19 ko RSV.
JinDun Medicalyana da haɗin gwiwar bincike na kimiyya na dogon lokaci tare da fasahar kere-kere tare da jami'o'in kasar Sin.Tare da wadataccen albarkatun kiwon lafiya na Jiangsu, tana da dangantakar kasuwanci ta dogon lokaci tare da Indiya, kudu maso gabashin Asiya, Koriya ta Kudu, Japan da sauran kasuwanni.Hakanan yana ba da sabis na kasuwa da tallace-tallace a cikin gabaɗayan tsari daga matsakaici zuwa ƙãre samfurin API.Yi amfani da tarin albarkatun Yangshi Chemical a cikin sinadarai na fluorine don samar da sabis na keɓance sinadarai na musamman ga abokan haɗin gwiwa.Samar da sabbin abubuwa da ayyukan bincike na ƙazanta don ƙaddamar da abokan ciniki.
JinDun Medical ya nace akan ƙirƙirar ƙungiyar tare da mafarkai, yin samfuran tare da mutunci, ƙwarewa, tsauri, da fita gabaɗaya don zama amintaccen abokin tarayya da abokin abokan ciniki!Masu samar da mafita guda ɗaya, R&D na musamman da sabis na samarwa na musamman don matsakaicin magunguna da APIs, sana'amusamman samar da magunguna(CMO) da R&D na Pharmaceutical na musamman da masu samar da sabis (CDMO).Jindun zai raka ku don ciyar da COVID-19.
Lokacin aikawa: Dec-16-2022